DrugPatentWatch Database Preview

TRIZIVIR Drug Profile

Email this page to a colleague

« Back to Dashboard

Which patents cover Trizivir, and when can generic versions of Trizivir launch?

Trizivir is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in TRIZIVIR is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.

Summary for TRIZIVIR

US Patents:	0
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Clinical Trials:	20
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TRIZIVIR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIZIVIR
DailyMed Link:	TRIZIVIR at DailyMed

See drug prices for TRIZIVIR

Recent Clinical Trials for TRIZIVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
AIDS Clinical Trials Group	Phase 3
Ines Perez	Phase 4

See all TRIZIVIR clinical trials

Recent Litigation for TRIZIVIR

Identify potential future generic entrants

District Court Litigation

Case Name	Date
ASTRAZENECA PHARMACEUTICALS LP v. AGILA SPECIALTIES, INC	2015-08-06
ViiV Healthcare UK Ltd. v. Lupin Ltd.	2011-06-29
Glaxo Group Ltd. v. Lupin Ltd.	2008-08-29

See all TRIZIVIR litigation

PTAB Litigation

Petitioner	Date
	2015-01-08
	2014-06-02

See all TRIZIVIR litigation

Pharmacology for TRIZIVIR

Drug Class	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for TRIZIVIR

Tradename	Dosage	Ingredient	NDA	Submissiondate
TRIZIVIR	TABLET;ORAL	abacavir sulfate; lamivudine; zidovudine	021205	2011-03-22

US Patents and Regulatory Information for TRIZIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000	AB	RX	Yes	Yes

Expired US Patents for TRIZIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000

International Patents for TRIZIVIR

Country	Patent Number	Estimated Expiration
South Korea	960007531
Hong Kong	1009270
Malaysia	115461
Australia	572019

Supplementary Protection Certificates for TRIZIVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0817637	23/2005	Austria		PRODUCT NAME: KOMBINATION, UMFASSEND ABACAVIR BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES ESTERS ODER SOLVAT DAVON UND LAMIVUDIN BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES; REGISTRATION NO/DATE: EU/1/04/298/001, EU/1/04/298/002 20041217
0817637	C300195	Netherlands		PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDB AAR ZUURADDITIEZOUT, IN HET BIJZONDER HET HEMISULFAAT, EN LAMIV UDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRTION NO/DATE: EU/04/298/001-002 20041217
0382526	SZ 22/1996	Austria		PRODUCT NAME: LAMIVUDIN UND DESSEN PHARMAZEUTISCH ANNEHMBARE SALZE
0382526	C960025	Netherlands		PRODUCT NAME: LAMIVUDINUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/015/001 - EU/1/96/015/002 19960808